Publications by authors named "Catriona Harvey"
Article Synopsis
- Immune checkpoint inhibitor gastrointestinal toxicity (IRIGItox) commonly occurs in patients undergoing cancer treatment and can lead to serious health issues, particularly when steroids fail to manage the symptoms.
- A study analyzed 78 patients, mostly male and with melanoma, to explore treatment outcomes after two doses of infliximab failed to alleviate their gastrointestinal symptoms.
- The results indicated that calcineurin inhibitors were most effective for symptom resolution, achieving positive outcomes in 74% of cases, while other therapies showed lower success rates, confirming the need for effective management of infliximab-refractory cases.
Background: Immune checkpoint inhibitors are frequently associated with the development of immunotherapy-related adverse events (irAEs). The exact etiology, including the role of environmental factors, remains incompletely understood.
Methods: We analyzed the records of 394 melanoma patients from three centers (northern and southern hemisphere).
Background: Australia has one of the highest rates of asbestos-associated diseases. Mesothelioma remains an area of unmet need with a 5-year overall survival of 10%. First-line immunotherapy with ipilimumab and nivolumab is now a standard of care for unresectable pleural mesothelioma following the CheckMate 743 trial, with supportive data from the later line single-arm MAPS2 trial.
View Article and Find Full Text PDFDataset of a retrospective multicenter cohort study on characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis.
Data Brief
December 2022
Article Synopsis
- Over the past decade, cancer immunotherapy using immune checkpoint inhibitors (ICIs) has improved cancer treatment outcomes but has also led to an increase in neurological immune-related adverse events (irAEs), notably encephalitis.
- ICI-induced encephalitis (ICI-iE) can be severe, resulting in treatment discontinuation, lasting complications, or even death, yet there is limited data on its clinical characteristics and diagnostic criteria.
- This study gathered and analyzed 30 cases of ICI-iE alongside cases of anti-LGI1 and HSV-1 encephalitis to identify distinguishing features, aiming to enhance recognition, diagnosis, and management of ICI-iE.
Aim: Immune checkpoint inhibitor-induced encephalitis (ICI-iE) is a rare but life-threatening toxicity of immune checkpoint inhibitor treatment. We aim to identify the characteristics of ICI-iE and describe factors that discriminate it from herpes simplex virus (HSV)-1 encephalitis and anti-leucine-rich glioma-inactivated 1 (anti-LGI1) encephalitis, as two alternative entities of encephalitis.
Methods: In this retrospective multicentre cohort study, we collected patients with ICI-iE reported to the Side Effect Registry Immuno-Oncology from January 2015 to September 2021 and compared their clinical features and outcome with 46 consecutive patients with HSV-1 or anti-LGI1 encephalitis who were treated at a German neurological referral centre.
Background: Programmed cell death receptor-1 (PD-1) monotherapy is a standard treatment for advanced cutaneous melanoma, but its efficacy and toxicity are defined in white populations and remain poorly characterized in other ethnic groups, such as East Asian, Hispanic and African.
Objectives: To determine the efficacy and toxicity of PD-1 monotherapy in different ethnic groups.
Methods: Clinical data for patients with unresectable or advanced melanoma treated with anti-PD-1 monotherapy between 2009 and 2019 were collected retrospectively from five independent institutions in the USA, Australia and China.
Purpose: Programmed cell death receptor-1 (PD-1) inhibitors are frontline therapy in advanced melanoma. Severe immune-related adverse effects (irAEs) often require immunosuppressive treatment with glucocorticoids (GCCs), but GCC use and its correlation with patient survival outcomes during anti-PD-1 monotherapy remains unclear.
Experimental Design: In this multicenter retrospective analysis, patients treated with anti-PD-1 monotherapy between 2009 and 2019 and detailed GCC use, data were identified from five independent cohorts, with median follow-up time of 206 weeks.